EXHIBIT 10.17
*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
CORIXA LICENSE AGREEMENT
THIS CORIXA LICENSE AGREEMENT (together with the exhibits hereto, this
"Agreement") is made and entered into effective as of January 28, 2003, by and
among Corixa Corporation, a Delaware corporation with its principal place of
business located at 0000 Xxxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxx, Xxxxxxxxxx 00000
("Corixa") and SmithKline Xxxxxxx plc, a company established in the United
Kingdom with its registered office at 000 Xxxxx Xxxx Xxxx, Xxxxxxxxx, Xxxxxxxxx
XX0 0XX, Xxxxxx Xxxxxxx ("GSK"). Each of Corixa and GSK may be referred to
herein as a "Party" and together as the "Parties."
RECITALS
WHEREAS, Corixa and GSK are parties to that certain Multi-Field
Agreement (as defined herein) pursuant to which GSK has the right to research,
develop and commercialize certain immunotherapy products for use with specific
diseases or conditions affecting humans;
WHEREAS, the R&D Programs conducted under the Multi-Field Agreement and
directed to the BC Field, OC Field, PC Field, CC Field and Her2/neu-Mammaglobin
Field, as such terms are defined under the Multi-Field Agreement, were
terminated on June 15, 2002;
WHEREAS, subject to the terms and conditions set forth herein,
including without limitation, certain rights granted to GSK by Corixa, GSK and
Corixa desire that Corixa have the right to research, develop, and under certain
circumstances, commercialize, under this Agreement, Corixa Products with the
possibility, thereby, of generating revenue for both Parties and validating
certain intellectual property assets resulting from the Parties' collaborative
efforts under the Multi-Field Agreement (as defined herein).
NOW, THEREFORE, in consideration of the foregoing premises and other
good and valuable consideration the receipt and sufficiency of which are hereby
acknowledged, the Parties hereby agree as follows:
SECTION 1
DEFINITIONS
Unless otherwise specifically provided herein, the following terms
shall have the following meanings:
1.1 "AAA" shall have the meaning set forth in Section 12.6.
1.2 "ADJUVANT" shall mean a composition owned or Controlled by
Corixa that is used for the sole purpose of generating or increasing an immune
response to and when used in conjunction with a Protein Product, a DNA Therapy
Product or a DC Therapy Product. For the
avoidance of doubt, Adjuvant shall not include any GSK Adjuvant(s) as defined in
the Collaboration Agreement.
1.3 "AFFILIATE" shall mean any entity owned, owning or under
common ownership with a Party to this Agreement to the extent of at least fifty
percent (50%) of the equity (or such lesser percentage which is the maximum
allowed to be owned by a foreign corporation in a particular jurisdiction)
having the power to vote on or direct the affairs of the entity and any person,
firm, partnership, corporation or other entity actually controlled by,
controlling or under common control with such entity. Notwithstanding the
foregoing, neither Party shall be an "Affiliate" of the other Party, or any of
its respective Affiliates, for the purposes of this Agreement.
1.4 "AGGREGATE SUBLICENSE PAYMENT" shall have the meaning set
forth in Section 5.2.
1.5 "AMENDED MFA" shall mean the Multi-Field Agreement as amended
by Amendment No. 2 as of the Effective Date.
1.6 "AMENDED MFA PRODUCTS" shall mean all products with regard to
which Corixa granted GSK a license pursuant to the terms of the Amended MFA.
1.7 "ANTIBODY" shall mean an immunoglobulin capable of binding to
a specific Antigen and/or an immunoglobulin [*] capable of binding to a specific
Antigen and/or a [*] an immunoglobulin [*], which [*] is capable of binding to a
specific Antigen.
1.8 "ANTIBODY-BASED PRODUCTS" shall mean products comprised of or
including one or more monoclonal and/or polyclonal Antibodies for use in passive
immune therapy; provided however, that such Antibodies are generated through the
use of Antigens as targets.
1.9 "ANTIGENS" shall mean (i) antigens and/or (ii) proteins and/or
(iii) other physical forms based on such antigens, such as [*] and/or [*] and/or
[*] and/or [*], including [*], but no other [*], except in the case of antigens
for [*] and [*], which may include [*] for [*], and/or [*] thereof, based on
such antigens in each case, delivered in any form including, but not restricted
to, [*], whether [*] or not.
1.10 "[*] ANTIBODY" shall mean a [*] or [*] Antibody wherein the
[*] of such Antibody [*] a [*] and/or [*] immune response directed [*] such [*].
For avoidance of doubt, in no case shall the term [*] Antibody mean or include
an Antibody that will bind to an Antigen.
1.11 "BC ANTIGENS" shall mean the Antigens identified on Exhibit
1.11 attached hereto.
1.12 "BREACHING PARTY" shall have the meaning set forth in Section
9.2.
1.13 "CC ANTIGENS" shall mean the Antigens identified on Exhibit
1.13 attached hereto.
-----------------------------------
* Confidential treatment requested.
2
1.14 "COLLABORATION AGREEMENT" shall mean the Collaboration and
License Agreement entered into by and between Corixa and GSK as of the Effective
Date.
1.15 "CONTROL" OR "CONTROLLED" shall mean, with respect to any
data, results, information, inventions, know-how, formulas, trade secrets,
techniques, methods, procedures, development, material or compositions of matter
of any type or kind, whether or not patentable, or any intellectual property
right, possession of the ability, whether by ownership or license, to assign,
grant a license, sublicense, immunities or other rights as provided for herein
to such item or under such right without violating the terms of any agreement or
other arrangement with any Third Party.
1.16 "CORIXA FIELD(S)" shall mean the research, development,
manufacture, use and sale of the following products for use within the Field:
(a) Protein Products that include one or more OC
Antigens;
(b) DNA Therapy Products that include one or more OC
Antigens;
(c) Antibody-Based Products that include one or more OC
Antigens;
(d) T Cell-Based Products that include one or more OC
Antigens;
(e) TDM Products that include one or more OC Antigens;
(f) DC Therapy Product that include one or more OC
Antigens;
(g) T Cell-Based Products that include one or more
Mammaglobin Antigens;
(h) T Cell-Based Products that include one or more CC
Antigens;
(i) T Cell-Based Products that include one or more PC
Antigens;
(j) T Cell-Based Products that include one or more BC
Antigens;
(k) T Cell-Based Products that include one or more
Her2/neu Antigens;
(l) TDM Products that include one or more Mammaglobin
Antigens;
(m) TDM Products that include one or more CC Antigens;
(n) TDM Products that include one or more PC Antigens;
(o) TDM Products that include one or more BC Antigens;
and
(p) TDM Products that include one or more Her2/neu
Antigens.
3
1.17 "CORIXA PRODUCTS" shall mean products for use in one or more
of the Corixa Fields (such use to be determined by the [*] in the [*] and [*]
such products or services), and that are sold by, or offered for sale on behalf
of, Corixa, its Affiliates or Sublicensees.
1.18 "CSC" shall have the meaning ascribed to it in the
Collaboration Agreement.
1.19 "DC THERAPY PRODUCTS" shall mean products comprised in whole
or in part of [*] with an Antigen for the primary purpose and effect of inducing
a prophylactic and/or therapeutic immune response specific to such Antigen or
one or more epitopes contained therein.
1.20 "DEFAULT" shall have the meaning set forth in Section 9.2
hereof.
1.21 "DISPUTE" shall have the meaning set forth in Section 12.6.
1.22 "DNA THERAPY PRODUCTS" shall mean products consisting of an
Antigen in the form of a [*], delivered in any form or configuration, including
without limitation, as a [*] or without the use of a [*], whether or not [*],
that is administered for the primary purpose and effect of inducing a
prophylactic or therapeutic immune response specific to such Antigen or one or
more [*] contained therein.
1.23 "EFFECTIVE DATE" shall mean the effective date of this
Agreement as set forth in the first paragraph hereof.
1.24 "EXECUTION DATE" shall have the meaning set forth in Section
5.2.
1.25 "FDA" shall mean the United States Food and Drug
Administration and any successor agency or authority thereto.
1.26 "FIELD" shall mean any and all forms of cancer in humans.
1.27 "FIRST COMMERCIAL SALE" shall mean, on a country-by-country
basis, the date of the first arm's length transaction, transfer or disposition
for value to a Third Party of a Corixa Product by or on behalf of Corixa or any
Affiliate or Sublicensee of Corixa in such country.
1.28 "GSK ADJUVANT" shall have the meaning ascribed to it in the
Collaboration Agreement.
1.29 "GSK KNOW-HOW" shall mean all technical information, materials
and know-how that exists at the time of the Effective Date and is Controlled by
GSK with the right to grant sublicenses, that directly relates to the research
development or commercialization of products in the OC Field and shall include,
without limitation, [*] and [*] data and any [*] or [*] directly related to the
OC Field. In no event will the term "GSK Know-How" include (i) the Licensed
Know-How or any of it or (ii) any technical information, materials and know-how
that relates generally to [*] or other [*] technology and/or to GSK Adjuvants.
-----------------------------------
* Confidential treatment requested.
4
1.30 "GSK PATENTS" shall mean all patents and patent applications
that are now and/or in the future Controlled by GSK (other than jointly with
Corixa) that generically or specifically claim any Antigen discovered during and
as a result of performance of the R&D Program as directed to the Field and
included in a Corixa Product and/or all or part of a Corixa Product(s), if any.
Included within the definition of GSK Patents are any continuations,
continuations-in-part, divisions, patents of addition, reissues, renewals or
extensions thereof, including, without limitation the Patents set forth on
Exhibit 1.30, which exhibit shall be kept current by prompt written notice to
Corixa of any additions or other changes thereto. In no event will the term "GSK
Patents" include the Licensed Patents or any of them.
1.31 "GSK PROGRAM INVENTIONS" shall have the meaning ascribed to it
in the Collaboration Agreement.
1.32 "GSK TDM PRODUCTS" shall mean a product that incorporates a
[*] Antigen(s) or Antibody(ies), or a [*] Antigen(s) or Antibody(ies) in any
format (provided that in the case of [*] may be incorporated in "GSK TDM
Products" only for [*]), solely for the purpose of (a) pre-screening human
patients to determine therapeutic eligibility for a Protein Product in either
the [*] Field or the [*] Field that incorporates or is based on such [*]
Antigen(s) or [*] Antigen(s), as applicable, or (b) for monitoring human
patients receiving such Protein Product in either the [*] Field or the [*]
Field, either during the clinical phase of development of such Protein Product
in either the [*] Field or the [*] Field or following commercialization thereof
(such uses are "GSK TDM Uses"). For further clarification, a GSK TDM Product can
only be associated commercially with [*] or [*] product administration and
cannot be [*] or [*] purely as a diagnostic product for use in [*] diagnosis,
diagnosis of [*] or diagnosis of [*] with the [*] for [*] with a product that is
not the related [*] Product that incorporates or is based on either a [*]
Antigen(s) or [*] Antigen(s), or for [*] to [*] other than a [*] Product in
either the [*] Field or the [*] Field. Further, a GSK TDM Product shall not be
commercialized in any country prior to the [*] for [*] of the [*] Product that
incorporates or is based on either a [*] Antigen(s) or [*] Antigen(s), as
applicable, in such country.
1.33 "GSK TDM USES" shall have the meaning set forth in Section
1.32.
1.34 "HER2/NEU ANTIGENS" shall mean those Antigens that are covered
by the patents so identified on Exhibit 1.40 attached hereto.
1.35 "HER2/NEU FIELD" shall mean the research, development and
commercialization of a product that incorporates one (1) or more Her2/neu
Antigens for use in the Field.
1.36 "INDEMNIFIED PARTY" shall have the meaning set forth in
Section 10.2.
1.37 "INDEMNIFYING PARTY" shall have the meaning set forth in
Section 10.2.
1.38 "JOINT PROGRAM INVENTIONS" shall have the meaning ascribed to
it in the Collaboration Agreement.
-----------------------------------
* Confidential treatment requested.
5
1.39 "LICENSED KNOW-HOW" shall mean all technical information,
materials and know-how Controlled by GSK, with the right to grant sublicenses as
a result of GSK's licenses from Corixa under the Amended MFA that directly
relates to, or is useful for the research, development or commercialization of
Corixa Products and shall include, without limitation, all [*] and [*] data and
any [*] or [*].
1.40 "LICENSED PATENTS" shall mean the "Corixa Patents," the "Joint
R&D Program Patents" and any "SPCs," collectively, as such terms are defined in
the Amended MFA including, without limitation, the Patents listed on Exhibit
1.40.
1.41 "LICENSED THERAPEUTIC" shall mean a Corixa Product, Proof of
Principle Product or Amended MFA Product for therapeutic use.
1.42 "LOSSES" shall have the meaning set forth in Section 10.1.
1.43 "MAMMAGLOBIN ANTIGENS" shall mean those Antigens that are
covered by the patents so identified on Exhibit 1.40 attached hereto.
1.44 "MULTI-FIELD AGREEMENT" shall mean the Multi-Field Vaccine
Discovery Collaboration and License Agreement between the Parties dated
September 1, 1998, as amended by Amendment No. 1 dated May 25, 2000, as further
amended by that certain letter agreement by and between the Parties dated
November 30, 2000, and as further amended by those certain letter agreements by
and between the Parties dated: (i) January 21, 2000, (ii) September 1, 2000,
(iii) a further letter agreement dated September 1, 2000, (iv) November 30,
2000, (v) August 16, 2001, (vi) April 17, 2002, (vii) October 14, 2002 and
(viii) a further letter agreement dated October 14, 2002.
1.45 "NEW CORIXA ANTIGENS" shall have the meaning set forth in
Section 1(iiii) of the Amended MFA.
1.46 "OC ANTIGENS" shall mean the Antigens identified on Exhibit
1.46 attached hereto.
1.47 "OC Field" shall mean ovarian cancer in humans.
1.48 "OPTION PERIOD" shall have the meaning set forth in Section
3.1.
1.49 "OVARIAN OPTION" shall have the meaning set forth in Section
3.1
1.50 "PATENT(S)" shall mean all patents and patent applications,
including, without limitation, any divisions, continuations,
continuations-in-part, reissues, renewals, extensions, and supplementary
protection certificates, as well as any certificates of invention or
applications therefor.
1.51 "PC ANTIGENS" shall mean the Antigens identified on Exhibit
1.51 attached hereto.
-----------------------------------
* Confidential treatment requested.
6
1.52 "PC FIELD" shall mean prostate cancer in humans.
1.53 "PERSON" shall mean an individual, sole proprietorship,
partnership, limited partnership, limited liability partnership, corporation,
limited liability company, business trust, joint stock company, trust,
unincorporated association, joint venture, or other similar entity or
organization, including, without limitation, a government or political
subdivision, department, or agency of a government.
1.54 "PLATFORM" shall mean a specific technology, technique,
process, system or approach to developing, configuring or devising a TDM Product
or GSK TDM Product.
1.55 "PROGRAM TERM" shall have the meaning ascribed to it in the
Collaboration Agreement.
1.56 "PROOF OF PRINCIPLE PRODUCTS" shall mean all products for
which Corixa granted a license to GSK pursuant to the terms of the Proof of
Principle Option, as defined in Section 3.1.2 of the Collaboration Agreement.
1.57 "PROTEIN PRODUCTS" shall mean products designed to generate an
immune response to an Antigen which products consist of an Antigen in the form
of a protein and/or [*] and/or an [*], delivered in any form or configuration,
whether or not [*] with an [*], that is administered for the primary purpose and
effect of inducing a prophylactic or therapeutic immune response, either for [*]
and/or [*] specific to such Antigen or one or more [*] contained therein.
1.58 "R&D Program" shall have the meaning set forth in Section
1(bbbbb) of the Amended MFA.
1.59 "SUBLICENSEE" shall mean a Third Party to whom Corixa has
granted a license, sublicense, immunities or other rights to any of the rights
licensed to Corixa under Section 2 hereof.
1.60 "SUBLICENSE PROCEEDS" shall mean the amounts received by
Corixa from a Sublicensee in consideration of a grant of rights to any of the
rights licensed to Corixa under Section 2 hereof, including, [*] payments, [*]
and [*], [*] fees, but excluding payments for [*] or [*] of Corixa Products,
payments for [*] and [*], and any [*] above the [*].
1.61 "T CELL-BASED PRODUCT" shall mean a product consisting in
whole or in part of ex vivo-cultured T cells that react specifically to one or
more Antigens for providing passive immune therapy.
1.62 "TDM DEVELOPMENT PERIOD" shall have the meaning set forth in
Section 3.2.
1.63 "TDM USES" shall have the meaning set forth in Section 1.66.
1.64 "TERM" shall have the meaning set forth in Section 9.1 hereof.
-----------------------------------
* Confidential treatment requested.
7
1.65 "TERMINATING PARTY" shall have the meaning set forth in
Section 9.2.
1.66 "THERAPEUTIC DRUG MONITORING PRODUCTS" or "TDM PRODUCT(S)"
shall mean products that use an Antigen(s) and/or Antibody in any format,
provided that in the case of [*] may be incorporated in TDM Products only for
[*], solely for the purpose of pre-screening human patients to determine
therapeutic eligibility for a Licensed Therapeutic that incorporates or is based
on such Antigen(s), or for monitoring human patients receiving such Licensed
Therapeutic, either during the clinical phase of development of such Licensed
Therapeutic or following commercialization thereof (such uses are "TDM Uses").
For further clarification, a TDM Product can only be associated commercially
with [*] or [*] product administration and cannot be [*], [*] purely as a
diagnostic product for use in [*] diagnosis, diagnosis of [*] or [*] with the
[*] for [*] with a product that is not a related [*], or for [*] to [*] other
than [*]. Further, a TDM Product shall not be commercialized in any country
prior to the [*] for [*] of the [*] in such country.
1.67 "THIRD PARTY" shall mean any Person other than Corixa, GSK and
their respective Affiliates.
1.68 "UPFRONT SUBLICENSE CONSIDERATION" shall mean all amounts to
be received by Corixa from a Sublicensee up to and including product approval,
in consideration of a grant of rights to any of the rights licensed to Corixa
under Section 2 hereof, including, without limitation, [*] payments, [*] fees
and payments for [*] and [*] and the [*], however calculated or characterized,
paid on the purchase of [*], but excluding payments for the [*] or [*] of any
Corixa Products and for [*] except for [*].
1.69 "UPFRONT SUBLICENSE PAYMENT" shall have the meaning set forth
in Section 5.2.
1.70 "[*] AGREEMENT" shall have the meaning set forth in Section
11.1(f).
1.71 "WORK PLAN" shall have the meaning ascribed to it in the
Collaboration Agreement.
1.72 "[*] AGREEMENT" shall have the meaning set forth in Section
11.1(f).
SECTION 2
LICENSE GRANT
2.1 LICENSE GRANT TO CORIXA BY GSK. Subject to the terms and
conditions set forth herein, including, without limitation, certain rights of
GSK set forth in Sections 2.2, 3.1 and 3.2 hereof, GSK hereby grants to Corixa
(i) an exclusive (even as to GSK), royalty-bearing, worldwide license or
sublicense, as applicable, with the right to grant Sublicenses, under GSK's
right, title and interest in and to the Licensed Patents, Licensed Know-How, GSK
Program Inventions and the Joint Program Inventions, and (ii) a non-exclusive,
royalty-free, worldwide license or sublicense, as applicable, with the right to
grant Sublicenses, under GSK's right, title and interest in and to any GSK
Patents, in both cases, solely to research, develop, make, have
-----------------------------------
* Confidential treatment requested.
8
made, use, have used, sell, offer for sale, have sold, keep and import Corixa
Products and for no other purpose.
2.1.1 CONVEYANCE OF CERTAIN LICENSED RIGHTS. Upon Corixa's
completion of the research and development work set forth in the Work Plan,
ownership of all right, title and interest in and to any and all intellectual
property rights to the Licensed Patents and Licensed Know-How, which are subject
to the license granted to Corixa under Section 2.1 hereof, shall automatically
revert to Corixa with no further action required by either Party.
Notwithstanding the foregoing, in the event the CSC terminates the research and
development work under the Work Plan because of technical infeasibility, safety
concerns or such other reasons as they shall determine to be appropriate, for
purposes of Section 4.4 of the Collaboration Agreement, the research and
development work set forth in the Work Plan shall be deemed to be completed and
the reversion described above shall automatically occur. GSK hereby agrees and
covenants to take such actions, including without limitation, to execute and
deliver such documents, as may be necessary or convenient to give effect to such
reversion as Corixa may reasonably request during the Term or thereafter.
2.1.2 PERPETUAL LICENSE GRANT. Upon the conveyance of the
rights described in Section 2.1.1 above, the license granted to Corixa under
Section 2.1 with respect to GSK Know-How, GSK Program Inventions and the Joint
Program Inventions shall automatically become perpetual and irrevocable, unless
Corixa is in breach of its payment obligation(s) hereunder and does not cure
such breach in accordance with Section 9.2, in which case GSK shall have the
right to terminate such license effective upon written notice to Corixa. GSK
hereby agrees and covenants to take such actions, including without limitation,
to execute and deliver such documents, as may be necessary or convenient to
give effect to such license grant as Corixa may reasonably request during the
Term or thereafter.
2.2 LICENSE GRANT-BACK TO GSK.
2.2.1 GSK TDM PRODUCTS LICENSE GRANT. Subject to the terms
and conditions set forth herein, including without limitation the remainder of
this Section 2.2.1, Corixa hereby grants to GSK a royalty-bearing license or
sublicense, as applicable, with the right to grant further sublicenses, under
the Licensed Patents and the Licensed Know-How, to research, develop, make, have
made, use, have used, sell, offer for sale, have sold, keep and import GSK TDM
Products solely for GSK TDM Uses, such rights to be exclusively or
non-exclusively licensed to GSK as follows. Such license shall be non-exclusive
with respect to GSK TDM Uses of [*]. Products for use in the [*] Field. Such
license, as it pertains to the GSK TDM Uses of [*] Products in the [*] Field
shall be exclusive or non-exclusive as it relates to a particular Platform as
set forth herein. If GSK identifies a Platform for use with [*] Products in the
[*] Field before the [*] anniversary of the Effective Date, or if GSK identifies
such a Platform after the [*] anniversary of the Effective Date and exclusive
rights for the use of such Platform with Protein Products in the [*] Field are
still available, then such rights shall be granted to GSK on an exclusive basis.
Otherwise, such license as it pertains to the GSK TDM Uses of [*] Products in
-----------------------------------
* Confidential treatment requested.
9
the [*] Field shall be non-exclusive. GSK hereby acknowledges that Corixa may
disclose any Platform identified to it by GSK to any potential TDM Product
Sublicensees. For avoidance of doubt, on an Antigen-by-Antigen and
Antibody-by-Antibody basis, GSK may select one (1) Platform for each Antigen or
Antibody that GSK desires to use in a GSK TDM Product.
2.2.2 LICENSE OF TDM PRODUCT RIGHTS BY CORIXA. Corixa shall
not grant a license, option or other rights in or to any TDM Product or GSK TDM
Product that would invalidate or restrict the GSK TDM Product rights granted to
GSK pursuant to Sections 2.2.1 and 3.2 hereof, as such rights relate to any
Amended MFA Product or Proof of Principle Option Product that includes one or
more CC Antigens, PC Antigens, BC Antigens, Her2/neu Antigens, or Mammaglobin
Antigens.
SECTION 3
GSK RIGHT OF FIRST NEGOTIATION; ADDITIONAL TDM PRODUCT RIGHTS;
TERMINATION OF RIGHT OF FIRST REFUSAL
3.1 GSK RIGHT TO NOTICE AND NEGOTIATION. Corixa shall provide GSK
with written notice of its intent to commence partnering discussions regarding
any and/or all Corixa Products that incorporate or are based on an OC Antigen.
GSK shall have [*] days (the "Option Period") from receipt of such notice to
initiate good faith negotiations with Corixa towards an agreement for the
development and commercialization of any or all Corixa Products (other than TDM
Products) that incorporate or are based on an OC Antigen (the "Ovarian Option");
provided, however, that Corixa shall be under no obligation to enter into such
an agreement with GSK, and provided, further, that in the event GSK provides
written notice of its intent not to exercise the Ovarian Option, or upon
expiration of the Option Period, Corixa shall have no further obligations under
the Ovarian Option.
3.2 PROOF OF PRINCIPLE PRODUCTS AND AMENDED MFA PRODUCTS RIGHTS.
If GSK requires the use of a TDM Product in order to initiate or continue
clinical trials of a Proof of Principle Product or an Amended MFA Product, then
GSK shall provide written notice of such need to Corixa not less than [*] in
advance of clinical trial initiation. Such notice shall include specifications
for such TDM Product in as much detail as GSK can reasonably provide. Corixa
shall have a period of [*] (the "TDM Development Period") from the receipt of
such notice to develop such a TDM Product for evaluation by GSK. If the TDM
Product developed by Corixa is satisfactory for GSK's requirements, then Corixa
(itself or through its Sublicensee of rights to such TDM Products, if any),
shall negotiate in good faith towards an agreement pursuant to which Corixa (or
its Sublicensee if applicable) will license rights to such TDM Product to GSK or
manufacture and supply such TDM Product to GSK, which license or supply shall
include the sub-licensable right for GSK to commercialize such TDM Product. If
GSK rejects such TDM Product, or if Corixa is unable to commit to manufacture
such TDM Product in sufficient quantities to support such clinical trials, then
Corixa shall grant to GSK a non-exclusive sub-licensable license under its
rights in TDM Products for a Platform that may be selected by GSK at anytime,
provided that such rights are available at the time of selection for the chosen
Platform, for GSK to develop, or have developed on its behalf, a TDM Product.
Prior to the
-----------------------------------
* Confidential treatment requested.
10
commercial launch of the associated Licensed Therapeutic GSK hereby agrees
that any TDM Product licensed pursuant to this Section 3.2 shall only be used
for internal research and development purposes. For avoidance of doubt, on an
Antigen-by-Antigen and Antibody-by-Antibody basis, GSK may select one (1)
Platform for each Antigen or Antibody that GSK desires to use in a TDM Product.
3.3 TERMINATION OF GSK RIGHT OF FIRST REFUSAL REGARDING CERTAIN
MONOCLONAL ANTIBODIES. The Parties hereby agree that the right of first refusal
granted by Corixa to GSK with regard to the monoclonal antibodies listed on
Exhibit 3.3 hereof, is terminated as of the date hereof and Corixa shall have no
further obligation to GSK with regard to such monoclonal antibodies.
SECTION 4
UPDATES AND ADVERSE EVENTS
4.1 UPDATES AND REPORTS. Corixa shall provide GSK with brief
written reports no less frequently than [*] during the Term (commencing with the
[*] of the Effective Date) summarizing Corixa's material efforts to develop and
commercialize Corixa Products hereunder. In addition, Corixa shall provide GSK
with prompt written notice of the occurrence of the First Commercial Sale of any
Corixa Product in any country. All reports, updates and other information
provided by one Party to the other Party under this Agreement (including under
this Section 4), shall be considered confidential information of the disclosing
Party, subject to the terms of Section 6 hereof.
4.2 ADVERSE EVENTS. During the Term, each Party shall promptly
inform the other of any information that it obtains or develops regarding the
utility and safety of any Corixa Product and shall promptly report to the other
any confirmed information of serious or unexpected reactions or side effects
related to the utilization or medical administration of a Corixa Product. Corixa
shall be exclusively responsible for reporting adverse events to the appropriate
regulatory bodies, in accordance with regulations and guidelines in effect, at
the time, in the relevant countries within the Territory. All such information
regarding adverse events and product complaints provided by one Party to the
other Party under this Agreement (including under this Section 4), shall be
considered confidential information of the disclosing Party, subject to the
terms of Section 6, provided, however, that the disclosing Party hereby consents
to the disclosure of such information to regulatory authorities to the extent
required by applicable laws.
SECTION 5
CONSIDERATION
5.1 PAYMENT TO GSK. In consideration of the licenses granted by
GSK hereunder, and subject to the other terms and conditions of this Agreement,
Corixa shall make royalty and milestone payments to GSK with regard to any
Corixa Product which is developed, commercialized and sold solely by Corixa that
would otherwise be applicable to GSK in accordance with the terms and conditions
of Sections 6 and 7 of the Amended MFA if GSK were commercializing such product.
Accordingly, relevant provisions of the Amended MFA are
-----------------------------------
* Confidential treatment requested.
11
hereby incorporated by reference into this Section 5.1, as are the definitions
of the capitalized terms used in such incorporated provisions, in accordance
with and subject to the following:
5.1.1 PROTEIN PRODUCTS AND DNA THERAPY PRODUCTS. All terms
and conditions applicable to Vaccine Products under Sections 6 and 7 of the
Amended MFA shall apply, for purposes of this Section 5.1, to Protein Products
and DNA Therapy Products.
5.1.2 ANTIBODY-BASED PRODUCTS. All terms and conditions
applicable to Antibody-Based Passive Immunotherapy Products under Sections 6 and
7 of the Amended MFA shall apply, for purposes of this Section 5.1, to
Antibody-Based Products.
5.1.3 DC THERAPY PRODUCTS. All terms and conditions
applicable to Existing DC Therapy Products or New DC Therapy Products under
Sections 6 and 7 of the Amended MFA shall apply, for purposes of this Section
5.1, to DC Therapy Products.
5.1.4 T CELL-BASED PRODUCTS. All terms and conditions
applicable to T Cell-Based Passive Immunotherapy Products under Sections 6 and 7
of the Amended MFA shall apply, for purposes of this Section 5.1, to T
Cell-Based Products.
5.1.5 TDM PRODUCTS. All terms and conditions applicable to
TDM Products under Sections 6 and 7 of the Amended MFA shall apply, for purposes
of this Section 5.1, to TDM Products; provided, however, it is agreed by the
Parties that Corixa shall have no payment obligations to GSK under Section 7 of
the Amended MFA with regard to TDM Products that do not include at least one New
Corixa Antigen.
5.2 SUBLICENSE PROCEEDS. If a Corixa Product is developed and/or
commercialized by a Sublicensee rather than directly by Corixa and/or an
Affiliate, Corixa shall pay to GSK [*] of all Sublicense Proceeds received by
Corixa (the "Aggregate Sublicense Payments") in consideration of a grant of
commercial rights in such Corixa Product to such Sublicensee. Within [*] days of
full execution and delivery of each such Sublicense agreement (the "Execution
Date") Corixa shall be obligated to pay to GSK,[*] of the Upfront Sublicense
Consideration (the "Upfront Sublicense Payment"). [*] Each Aggregate Sublicense
Payment, other than the Upfront Sublicense Payment, shall be due and payable
within [*] days of receipt by Corixa of each payment of Sublicense Proceeds. For
the avoidance of doubt, the Parties hereby acknowledge that Corixa shall have no
Aggregate Sublicense Payment or Upfront Sublicense Payment obligations to GSK
with regard to any diagnostic product other than TDM Products as provided
herein.
5.3 PAYMENT TO CORIXA. In consideration of the licenses granted by
Corixa to GSK hereunder, and subject to the other terms and conditions of this
Agreement, GSK shall make royalty payments to Corixa in accordance with the
terms and conditions applicable to TDM Products under Section 7 of the Amended
MFA. Accordingly, all such provisions are hereby incorporated by reference into
this Section 5.3, as are the definitions of the capitalized terms used in such
incorporated provisions; provided, however, all terms and conditions applicable
to TDM Products under Section 7 of the Amended MFA shall apply, for purposes of
this Section 5.3 to TDM Products and GSK TDM Products.
-----------------------------------
* Confidential treatment requested.
12
SECTION 6
CONFIDENTIALITY
6.1 CONFIDENTIALITY. During the Term, and for five (5) years
thereafter, Corixa and GSK shall not use or reveal or disclose to any Third
Party any confidential information received from the other Party or otherwise
developed by either Party in the performance of activities in furtherance of
this Agreement without first obtaining the written consent of the disclosing
Party, except as may be otherwise provided herein, or as may be required for
purposes of investigating, developing, manufacturing or marketing Corixa
Products or for securing essential or desirable authorizations, privileges or
rights from governmental agencies, or as required to be disclosed to a
governmental agency including without limitation, the FDA or the Securities and
Exchange Commission, or to carry out any litigation concerning Corixa Products;
provided, however, that in each such instance, the disclosing Party shall use
reasonable efforts to provide notice to the other Party prior to the first
disclosure of any particular item of confidential information and shall use
reasonable efforts to obtain confidential treatment of such confidential
information by the person or entity to which it is disclosed. In the event
Corixa requests GSK's consent to the inclusion of any GSK Know-How in any patent
filings, GSK shall not unreasonably withhold, condition or delay its consent.
This confidentiality obligation shall not apply to such information which is or
becomes a matter of public knowledge, or is already in the possession of the
receiving Party, or is disclosed to the receiving Party by a Third Party having
the right to do so, or is subsequently and independently developed by employees
of the receiving Party who had no knowledge of the confidential information
disclosed. The Parties shall take reasonable measures to assure that no
unauthorized use or disclosure is made by others to whom access to such
information is granted.
6.2 CORIXA PERMITTED DISCLOSURES. Nothing herein shall be
construed as preventing Corixa from disclosing any information received from GSK
to: (i) an Affiliate of Corixa, (ii) a Sublicensee or distributor solely in
connection with the exercise of Corixa's rights under this Agreement, or (iii) a
Third Party in connection with a potential investment, loan, merger or
acquisition transaction with Corixa; provided, however, that such Affiliate,
Sublicensee, distributor or Third Party has undertaken in writing a similar
obligation of confidentiality with respect to the confidential information, with
GSK named as a third party beneficiary thereof.
6.3 REQUIRED DISCLOSURES. All confidential information disclosed
by one Party to the other Party shall remain the property of the disclosing
Party. In the event that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or receiver, assumes partial or
complete control over the assets of a Party to this Agreement based on the
insolvency or bankruptcy of such Party, the bankrupt or insolvent Party shall
promptly notify, with a copy to the other Party, the court or other tribunal (i)
that confidential information received from the other Party under this Agreement
remains the property of the other Party and (ii) of the confidentiality
obligations under this Agreement. In addition, the bankrupt or insolvent Party
shall, to the extent permitted by law, take all steps necessary or desirable to
maintain the confidentiality of the other Party's confidential information and
to insure that the court, other tribunal or appointee maintains such information
in confidence in accordance with the terms of this Agreement.
13
6.4 PRESS RELEASE. The Parties may disclose the nature of this
Agreement in a joint press release following signature; provided, however, that
the releasing Party shall obtain the prior consent of the other Party on the
text of such press release, such consent not to be unreasonably withheld. In the
event that either Party reasonably determines that it is required by the
applicable laws of any jurisdiction, or the rules of any stock exchange on which
its securities are listed or traded, to publicly disclose information concerning
this Agreement or the rights and obligations of the Parties hereunder, including
without limitation, the circumstances under which money or other consideration
may become payable hereunder and the amount(s) of such payment(s), then such
Party shall provide the other Party with a reasonable opportunity to review the
text of such disclosure and the disclosing Party shall use reasonable best
efforts to implement the reasonable comments provided by the other Party while
still complying with such laws or rules.
SECTION 7
TECHNOLOGY TRANSFER
7.1 TECHNOLOGY TRANSFER. Promptly following the Effective Date,
GSK shall begin the process of making available to Corixa the technology
Controlled by GSK that is claimed by or comprises, in whole or in part, the
Licensed Patents, Licensed Know-How, GSK Patents, GSK Know-How, GSK Program
Inventions and Joint Program Inventions and is relevant to any Corixa Field.
SECTION 8
FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS
8.1 INTELLECTUAL PROPERTY MATTERS UNDER THE AMENDED MFA. The
filing, prosecution, maintenance and enforcement of all intellectual property
rights that are subject to this Agreement shall be governed by the Amended MFA.
SECTION 9
TERM AND TERMINATION
9.1 TERM. This Agreement shall commence upon the Effective Date
and shall remain in effect until expiration of the last-to-expire Licensed
Patent or GSK Patent unless it is terminated in accordance with this Section 9.
9.2 TERMINATION FOR MATERIAL BREACH. Failure by a Party (the
"Breaching Party") to comply with any of its material obligations contained
herein (a "Default") shall entitle the Party that is not in Default (the
"Terminating Party") to terminate this Agreement as provided for in this Section
9. Upon a Default, the Terminating Party shall give notice to the Breaching
Party specifying the nature of the Default, demanding that it cure such Default,
and stating its intention to terminate this Agreement if such Default is not
cured. If such Default is susceptible to cure but is not cured within ninety
(90) days after the receipt of such notice, then the Terminating Party shall be
entitled, without prejudice to any other rights conferred on it by this
Agreement, and in addition to any other remedies available to it by law or in
equity, to terminate this Agreement; provided, however, that any right to
terminate this Agreement shall be stayed in
14
the event that, during such ninety (90) day period, the Breaching Party shall
have initiated dispute resolution in accordance with Section 12.6 hereof with
respect to the alleged Default.
9.2.1 Upon a termination of this Agreement by GSK because
of a Default by Corixa, subject to the notice and cure provisions set forth in
this Section 9.2, all rights and licenses granted to Corixa hereunder shall
automatically terminate, free and clear of any obligation to Corixa under this
Agreement and GSK shall pay to Corixa royalties on any product commercialized by
it that incorporates or is based on any OC Antigen, including, but not limited
to products that incorporate or are based on Antibodies targeted to any OC
Antigen, equal to [*] of the royalty payments that would otherwise apply with
respect to such products under the terms and conditions of the Amended MFA,
except that for the duration of the Term (i) the licenses granted pursuant to
Section 2.1 shall continue in effect solely to the extent required to allow
Corixa to maintain in place any and all Sublicenses granted prior to such a
termination by GSK, subject to continued payment by Corixa of amounts due and
payable or which become payable pursuant to Section 5.2, as modified by
subsection 9.2.1(iv), hereof, (ii) the obligations of both Parties under
Sections 6 and 10 shall continue, (iii) the rights, licenses and options
confirmed or granted to GSK hereunder shall continue, provided that GSK shall
pay, for the remainder of the Term, in lieu of any payments it would otherwise
owe to Corixa under this Agreement, royalty payments equal to [*] percent of the
royalty payments that would otherwise apply with respect to TDM Products and GSK
TDM Products under Sections 2.2.1 and 3.2 hereof and (iv) Corixa's obligation to
pay a percentage of Sublicense Proceeds pursuant to Section 5.2 shall [*] in
connection with all Sublicense Proceeds received by Corixa on or after the
effective date of such termination.
9.2.2 Upon a termination of this Agreement by Corixa
because of a Default by GSK, subject to the notice and cure provisions set forth
in this Section 9.2, all rights, licenses and options confirmed or granted to
GSK hereunder shall automatically terminate, free and clear of any obligation to
GSK under this Agreement, except for the obligations of both Parties under
Sections 6 and 10 and Corixa shall automatically be conveyed (i) a fully
sublicensable, transferable, paid-up, perpetual, exclusive worldwide license
under GSK's right, title and interest in and to the GSK Patents and GSK
Know-How, GSK Program Inventions and Joint Program Inventions to research,
develop, make, have made, use, have used, sell, offer for sale, have sold, keep
and import Corixa Products, and (ii) ownership of all right, title and interest
in and to any and all intellectual property rights to the Licensed Patents and
Licensed Know-How, which are subject to the license granted to Corixa under
Section 2.1 hereof, with no further action required by either Party. GSK hereby
agrees and covenants to take such actions, including without limitation, to
execute and deliver such documents, as may be necessary or convenient to give
effect to the foregoing rights as Corixa may reasonably request.
9.3 TERMINATION UPON INSOLVENCY. This Agreement may be terminated
by either Party upon notice to the other Party should such other Party: (a)
consent to the appointment of a receiver or a general assignment for the benefit
of creditors, or (b) file or consent to the filing of a petition under any
bankruptcy or insolvency law or have any such petition filed against it which
has not been stayed within sixty (60) days of such filing.
-----------------------------------
* Confidential treatment requested.
15
9.4 RIGHTS IN BANKRUPTCY. All rights and licenses granted under or
pursuant to this Agreement are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to
"intellectual property" as defined under Section 101 of the U.S. Bankruptcy
Code.
9.5 CERTAIN CONSEQUENCES OF TERMINATION. Following are certain
consequences of the termination of this Agreement. This Section 9.5 does not set
forth all consequences of a termination of this Agreement which may arise
pursuant to the exercise of the Parties of their respective rights and remedies
arising hereunder or otherwise arising under law or equity.
9.5.1 REVERSION OF RIGHTS TO CORIXA. Upon the earlier of
the end of the Program Term and the expiration or termination of this Agreement
for any reason, other than a Default by Corixa, ownership of all of GSK's right,
title and interest in and to the Licensed Patents and Licensed Know-How that are
subject to this Agreement shall automatically be conveyed to Corixa. GSK hereby
agrees and covenants to take such actions, including without limitation, to
execute and deliver such documents, as may be necessary or convenient to give
effect to such license grant as Corixa may reasonably request during the Term or
thereafter.
9.6 ACCRUED RIGHTS; SURVIVING OBLIGATIONS. Termination of this
Agreement for any reason shall be without prejudice to any rights that shall
have accrued to the benefit of a Party prior to or on account of such
termination. All remedies provided hereunder or elsewhere are cumulative.
Sections 2.1.2 (other than in the case of termination due to Default by Corixa,
in which case Section 2.1.2 shall automatically terminate), 6, 8, 9.6, 10, 11,
12.4 and 12.5 of this Agreement shall survive the termination of this Agreement
for any reason and, Section 1 hereof shall survive such termination to the
extent any terms defined therein are used in such other surviving provisions.
SECTION 10
INDEMNITY
10.1 INDEMNIFICATION. Subject to Section 10.2 below, from and after
the Effective Date, except as otherwise herein specifically provided, each of
the Parties hereto shall defend, indemnify and hold harmless the other Party and
its successors and assigns, and their respective officers, directors,
shareholders, partners and employees from and against all losses, damage,
liability and expense including legal fees (but excluding punitive or
consequential damages (including lost profits)) ("Losses") incurred thereby or
caused thereto arising out of or relating to (i) any breach or violation of, or
failure to properly perform, any covenant or agreement made by such Indemnifying
Party (as defined in Section 10.2) in this Agreement, unless waived in writing
by the Indemnified Party (as defined in Section 10.2); (ii) any breach of any of
the representations or warranties made by such Indemnifying Party in this
Agreement; or (iii) the gross negligence or willful misconduct of the
Indemnifying Party.
10.2 INDEMNIFICATION PROCEDURE. If either Corixa or GSK (in each
case an "Indemnified Party") receives any written claim which it believes is the
subject of indemnity hereunder by either GSK or Corixa, as the case may be (in
each case an "Indemnifying Party") the Indemnified Party shall, as soon as
reasonably practicable after forming such belief, give notice thereof to the
Indemnifying Party, including full particulars of such claim to the extent
16
known to the Indemnified Party; provided, however, that the failure to give
timely notice to the Indemnifying Party as contemplated hereby shall not release
the Indemnifying Party from any liability to the Indemnified Party. The
Indemnifying Party shall have the right, by prompt notice to the Indemnified
Party, to assume the defense of such claim with counsel reasonably satisfactory
to the Indemnified Party, and at the cost of the Indemnifying Party. If the
Indemnifying Party does not so assume the defense of such claim, the Indemnified
Party may assume such defense with counsel of its choice at the sole expense of
the Indemnifying Party. If the Indemnifying Party so assumes such defense, the
Indemnified Party may participate therein through counsel of its choice, but the
cost of such counsel shall be borne solely by the Indemnified Party.
10.3 ASSISTANCE. The Party not assuming the defense of any such
claim shall render all reasonable assistance to the Party assuming such defense,
and all out-of-pocket costs of such assistance shall be borne solely by the
Indemnifying Party.
10.4 SETTLEMENT. No such claim shall be settled other than by the
Party defending the same, and then only with the consent of the other Party,
which shall not be unreasonably withheld; provided, however, that the
Indemnified Party shall have no obligation to consent to any settlement of any
such claim which imposes on the Indemnified Party any liability or obligation
which cannot be assumed and performed in full by the Indemnifying Party.
10.5 LIMITATION ON LOSSES. IN NO EVENT SHALL ANY PARTY OR ANY OF
THEIR AFFILIATES BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL
DAMAGES OF ANY OTHER PARTY, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT,
STRICT LIABILITY OR OTHERWISE, ARISING OUT OF (A) THE MANUFACTURE, USE OR SALE
OF ANY PRODUCT DEVELOPED OR MARKETED HEREUNDER OR (B) ANY BREACH OF OR FAILURE
TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT EXCEPT TO THE EXTENT REQUIRED
FOR AN INDEMNIFYING PARTY TO PROVIDE INDEMNITY TO AN INDEMNIFIED PARTY AGAINST
SUCH DAMAGES IN THE EVENT SUCH DAMAGES ARE SUCCESSFULLY ASSERTED AGAINST AN
INDEMNIFIED PARTY BY A THIRD PARTY.
SECTION 11
REPRESENTATIONS, WARRANTIES AND COVENANTS
11.1 REPRESENTATIONS, WARRANTIES AND COVENANTS OF CORIXA AND GSK.
Each Party hereby represents, warrants and covenants to the other Parties as of
the Effective Date as follows:
(a) Such Party has the power, authority and the legal
right to enter into this Agreement and to perform its obligations hereunder, and
has taken all necessary action on its part required to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder.
This Agreement has been duly executed and delivered on behalf of such Party and
constitutes a legal, valid, binding obligation of such Party and is enforceable
against it in accordance with its terms subject to the effects of bankruptcy,
insolvency, or other laws of general application affecting the enforcement of
creditor rights and judicial principles
17
affecting the availability of specific performance and general principles of
equity, whether enforceability is considered a proceeding at law or equity.
(b) Such Party is not aware of any pending or threatened
litigation (and has not received any communication) that alleges that such
Party's activities related to this Agreement have violated, or that by
conducting the activities as contemplated herein such Party would violate, any
of the intellectual property rights of any other person.
(c) The execution and delivery of this Agreement and the
performance of such Party's obligations hereunder do not conflict with or
violate any requirement of applicable law or regulation or any provision of
articles of incorporation, bylaws or limited partnership agreement of such
Party, as applicable, in any material way, and do not conflict with, violate, or
breach or constitute a default or require any consent under, any contractual
obligation or court or administrative order by which such Party is bound.
(d) Such Party is a legally organized entity and in good
standing under the laws of the state of its incorporation, and has full power
and authority and the legal right to own and operate its property and assets and
to carry on its business as it is now being conducted and as it is contemplated
to be conducted by this Agreement.
(e) EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE
PARTIES DISCLAIM ALL WARRANTIES WHATSOEVER, EITHER EXPRESS OR IMPLIED, INCLUDING
WARRANTIES AS TO THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.
(f) The Parties acknowledge that the license granted to
Corixa hereunder includes a sublicense under technology (i) licensed by Corixa
pursuant to: (a) a certain Amended and Restated Exclusive License Agreement
between [*] and Corixa, effective [*] (the "[*] Agreement") and (b) a certain
License Agreement between [*] and Corixa, effective [*] (the "[*] Agreement"),
and (ii) subsequently sublicensed by Corixa to GSK pursuant to the Amended MFA.
Each Party warrants and represents that it will comply with all applicable terms
and conditions of the [*] Agreement and the WU Agreement; provided, however,
that GSK shall not have any obligation to pay any license fees or royalty or
milestone payments under the [*] Agreement or the [*] Agreement except as
expressly provided for in the Amended MFA, and provided further, that if, as a
result of complying with the applicable terms and conditions of the [*]
Agreement or the [*] Agreement, GSK would be in breach of this Agreement, then
Corixa in its sole discretion shall determine whether the responsibility of such
compliance will be borne by Corixa and/or GSK, and such compliance shall not be
deemed to cause a breach of this Agreement by either Party.
11.2 ADDITIONAL REPRESENTATION AND COVENANT OF GSK.
(a) GSK hereby further represents to Corixa that as of
the Effective Date, there are no patents or patent applications, including
without limitation any continuations,
-----------------------------------
* Confidential treatment requested.
18
continuations-in-part, divisions, patents of addition, reissues, renewals or
extensions thereof, that are Controlled by GSK (other than jointly with Corixa)
and/or under which GSK otherwise has the right to grant licenses or sublicenses,
that generically or specifically claim any Antigen discovered during or as a
result of performance of the R&D Program as directed to the Field and included
in a Corixa Product and/or all or part of a Corixa Product(s).
(b) GSK hereby further covenants to provide Corixa with
prompt written notice of any additions or changes to Exhibit 1.30 attached
hereof.
SECTION 12
MISCELLANEOUS
12.1 FORCE MAJEURE. If the performance of any part of this
Agreement by any Party, or of any obligation under this Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the Party liable to perform, unless conclusive evidence to
the contrary is provided, the Party so affected shall, upon giving written
notice to the other Parties, be excused from such performance to the extent of
such prevention, restriction, interference or delay, provided that the affected
Party shall use its reasonable best efforts to avoid or remove such causes of
nonperformance and shall continue performance with the utmost dispatch whenever
such causes are removed. When such circumstances arise, the Parties shall
discuss what, if any, modification of the terms of this Agreement may be
required in order to arrive at an equitable solution.
12.2 ASSIGNMENT. Without the prior written consent of the other
Party hereto, neither Party shall sell, transfer, assign, delegate, pledge, or
otherwise dispose of, whether voluntarily, involuntarily, by operation of law or
otherwise, this Agreement or any of its rights or duties hereunder; provided,
however, that either Party may assign this Agreement, without the consent of the
other Party, to the purchaser or successor by merger, consolidation or change of
control of all or substantially all of its business or assets to which this
Agreement pertains.
12.3 SEVERABILITY.
(a) In the event any portion of this Agreement shall be held
illegal, void or ineffective, the remaining portions hereof shall remain in full
force and effect.
(b) If any of the terms or provisions of this Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law provided that such conformity is in accordance with the intent of
the Parties.
12.4 GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Washington, without
reference to the rules of conflict of laws thereof.
12.5 NOTICES. All notices or other communications that are required
or permitted hereunder shall be in writing and delivered personally, sent by
telecopier (and promptly confirmed by personal delivery, registered or certified
mail or overnight courier), sent by
19
nationally-recognized overnight courier or sent by registered or certified mail,
postage prepaid, return receipt requested, addressed as follows:
IF TO CORIXA, TO:
Corixa Corporation
0000 Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxx, Xxxxxxxxxx 00000
Attn: Chairman and Chief Executive Officer
with a copy to:
General Counsel
If to GSK, to:
SmithKline Xxxxxxx, plc
000 Xxxxx Xxxx Xxxx
Xxxxxxxxx, Xxxxxxxxx
XX0 0XX
Xxxxxx Xxxxxxx
Attn.: General Counsel
with a copy to:
GlaxoSmithKline Biologicals S.A.
00 xxx xx x'Xxxxxxxx
0000 Xxxxxxxxx
Xxxxxxx
Attn: President General Manager
or to such other address as the Party to whom notice is to be given may have
furnished to the other Party in writing in accordance herewith. Any such
communication shall be deemed to have been given: (i) when delivered, if
personally delivered or sent by telecopier on a business day, (ii) on the
business day after dispatch, if sent by nationally-recognized overnight courier,
and (iii) on the third business day following the date of mailing, if sent by
registered mail. It is understood and agreed that this Section 12.5 is not
intended to govern the day-to-day business communications necessary between the
Parties in performing their duties, in due course, under the terms of this
Agreement.
12.6 DISPUTE RESOLUTION.
(a) Prior to engaging in any formal dispute resolution
with respect to any dispute, controversy or claim arising out of or in relation
to this Agreement or the breach, termination or invalidity hereof (each, a
"Dispute"), the Chief Executive Officers of the Parties shall attempt over a
period of not less than sixty (60) days to resolve such Dispute. Such attempt
may at the request of a Party include a thirty (30) day period of mediation by a
Third Party whose selection is agreed upon by the Parties. In the event of
mediation, the Parties in dispute shall bear equally the costs associated with
the mediation.
20
(b) Any dispute, controversy or claim arising out of or
in relation to this Agreement or the breach, termination or invalidity hereof
that cannot be settled amicably by agreement of the Parties pursuant to Section
12.6(a) shall be finally settled by arbitration in accordance with the
arbitration rules of the American Arbitration Association ("AAA") then in force.
The place of arbitration shall be New York City, New York. The arbitrator's
award rendered shall be final and binding upon the Parties. Judgment upon the
award may be entered in any court having jurisdiction, or application may be
made to such court for judicial acceptance of the award and/or an order of
enforcement as the case may be.
12.7 MODIFICATIONS. No amendment, modification, release or
discharge hereof shall be binding upon the Parties unless in writing and duly
executed by authorized representatives of both Parties.
12.8 HEADINGS. The headings used in this Agreement are intended for
convenience only and shall not be considered part of the written understanding
between the Parties and shall not affect the construction of this Agreement.
12.9 EQUITABLE RELIEF. Notwithstanding anything herein to the
contrary, nothing in this Agreement shall preclude a Party from seeking interim
or provisional relief, in the form of a temporary restraining order, preliminary
injunction or other interim equitable relief concerning a dispute prior to or
during an arbitration pursuant to Section 12.6 necessary to protect the
interests of such Party.
12.10 WAIVER. The waiver by a Party hereto of any right hereunder or
the failure to perform or a breach by the other Party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other Party whether of a similar nature or otherwise.
12.11 COUNTERPARTS. This Agreement may be executed in two (2) or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
12.12 NO BENEFIT TO THIRD PARTIES. The representations, warranties,
covenants and agreements set forth in this Agreement are for the sole benefit of
the Parties hereto and their successors and permitted assigns, and they shall
not be construed as conferring any rights on any Third Parties.
12.13 FURTHER ASSURANCE. Each Party shall duly execute and deliver,
or cause to be duly executed and delivered, such further instruments and do and
cause to be done such further acts and things, including, without limitation,
the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the any other Party may reasonably request in connection with
this Agreement or to carry out more effectively the provisions and purposes
hereof, or to better assure and confirm unto such other Party its rights and
remedies under this Agreement.
12.14 CONSTRUCTION. Except where the context otherwise requires,
wherever used, the singular shall include the plural, the plural the singular,
the use of any gender shall be applicable to all genders and the word "or" is
used in the inclusive sense. The captions of this Agreement are for convenience
of reference only and in no way define, describe, extend or limit the scope or
21
intent of this Agreement or the intent of any provision contained in this
Agreement. The Parties have participated equally in the formation of this
Agreement; the language of this Agreement shall not be presumptively construed
against any Party.
12.15 ENTIRE AGREEMENT This Agreement including specifically
referenced and incorporated provisions of the Amended MFA, entered into as of
the Effective Date, constitutes the entire agreement between the Parties
relating to the subject matter hereof and supersedes all previous writings and
understandings, including, without limitation, the Multi-Field Agreement.
22
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their duly authorized representatives as of the date first above
written.
CORIXA CORPORATION SMITHKLINE XXXXXXX PLC
By: /s/ XXXXXX XXXXXX By: /s/ JEAN STEPHENNE
--------------------------- ------------------------
Name: Xxxxxx Xxxxxx Name: Jean Stephenne
--------------------------- ------------------------
Title: CEO Title: Attorney
--------------------------- ------------------------
23
EXHIBIT 1.11
BC Antigens
ANTIGEN NAME
BREAST TISSUE DATE ENTERED INTO THE DATABASE
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
-----------------------------------
* Confidential treatment requested.
24
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
-----------------------------------
* Confidential treatment requested.
25
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
[*] Breast [*]
-----------------------------------
* Confidential treatment requested.
26
EXHIBIT 1.13
CC Antigens
COLON
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
-----------------------------------
* Confidential treatment requested.
27
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
-----------------------------------
* Confidential treatment requested.
28
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
-----------------------------------
* Confidential treatment requested.
29
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
-----------------------------------
* Confidential treatment requested.
30
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
[*] Colon [*]
-----------------------------------
* Confidential treatment requested.
31
EXHIBIT 1.30
GSK Patents
EXHIBIT 1.40
Licensed Patents
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
2
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
3
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
4
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
5
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
6
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
7
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
8
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
9
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
10
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
11
----------------------------------------------------------------------------------------------------------------
BREAST CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
12
----------------------------------------------------------------------------------------------------------------
PROSTATE CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
13
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
14
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
15
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
16
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
17
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
18
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
19
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
20
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
COLON CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
20
----------------------------------------------------------------------------------------------------------------
COLON CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
22
----------------------------------------------------------------------------------------------------------------
COLON CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
23
----------------------------------------------------------------------------------------------------------------
COLON CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
24
----------------------------------------------------------------------------------------------------------------
COLON CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
25
----------------------------------------------------------------------------------------------------------------
COLON CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
OVARIAN CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
26
----------------------------------------------------------------------------------------------------------------
OVARIAN CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
27
----------------------------------------------------------------------------------------------------------------
OVARIAN CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
28
----------------------------------------------------------------------------------------------------------------
OVARIAN CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
29
----------------------------------------------------------------------------------------------------------------
OVARIAN CANCER
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
30
----------------------------------------------------------------------------------------------------------------
HER-2/NEU
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
31
----------------------------------------------------------------------------------------------------------------
HER-2/NEU
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
32
----------------------------------------------------------------------------------------------------------------
HER-2/NEU
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
33
----------------------------------------------------------------------------------------------------------------
HER-2/NEU
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
MAMMAGLOBIN
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
34
----------------------------------------------------------------------------------------------------------------
MAMMAGLOBIN
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
35
----------------------------------------------------------------------------------------------------------------
MAMMAGLOBIN
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
36
----------------------------------------------------------------------------------------------------------------
MAMMAGLOBIN
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
37
----------------------------------------------------------------------------------------------------------------
MAMMAGLOBIN
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
38
----------------------------------------------------------------------------------------------------------------
MAMMAGLOBIN
----------------------------------------------------------------------------------------------------------------
CASE NUMBER COUNTRY APP. NO./FILING DATE PATENT NO./ISSUE DATE STATUS
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
[*] [*] [*] [*] [*]
----------------------------------------------------------------------------------------------------------------
-----------------------------------
* Confidential treatment requested.
39
EXHIBIT 1.46
OC Antigens
ANTIGEN NAME TISSUE DATE ENTERED INTO DATABASE
------------------------------------------------------------------------
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
-----------------------------------
* Confidential treatment requested.
40
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
-----------------------------------
* Confidential treatment requested.
41
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
[*] Ovarian [*]
-----------------------------------
* Confidential treatment requested.
42
EXHIBIT 1.51 CONTINUED
[*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
-----------------------------------
* Confidential treatment requested.
EXHIBIT 1.51 CONTINUED
PROSTATE
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
[*] Prostate [*]
-----------------------------------
* Confidential treatment requested.
EXHIBIT 3.3
Monoclonal Antibodies Subject to GSK Right of First Refusal
[*]
-----------------------------------
* Confidential treatment requested.
